WO1997014792A3 - Oligonucleotides with anti-respiratory syncytial virus activity - Google Patents

Oligonucleotides with anti-respiratory syncytial virus activity Download PDF

Info

Publication number
WO1997014792A3
WO1997014792A3 PCT/US1996/013307 US9613307W WO9714792A3 WO 1997014792 A3 WO1997014792 A3 WO 1997014792A3 US 9613307 W US9613307 W US 9613307W WO 9714792 A3 WO9714792 A3 WO 9714792A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
respiratory syncytial
syncytial virus
virus activity
disclosed
Prior art date
Application number
PCT/US1996/013307
Other languages
French (fr)
Other versions
WO1997014792A2 (en
Inventor
Robert E Kilkuskie
Patrick E Brown-Vargas
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Priority to AU68483/96A priority Critical patent/AU6848396A/en
Publication of WO1997014792A2 publication Critical patent/WO1997014792A2/en
Publication of WO1997014792A3 publication Critical patent/WO1997014792A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are oligonucleotides which hybridize to a portion of respiratory syncytial virus (RSV) genomic RNA under physiological conditions, and, in doing so, inhibit viral replication. Also disclosed are pharmaceutical compositions and methods useful for inhibiting and treating RSV infection and including at least one or two of these oligonucleotides, or at least one of these oligonucleotides and ribavirin.
PCT/US1996/013307 1995-10-17 1996-08-19 Oligonucleotides with anti-respiratory syncytial virus activity WO1997014792A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU68483/96A AU6848396A (en) 1995-10-17 1996-08-19 Oligonucleotides with anti-respiratory syncytial virus activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54413095A 1995-10-17 1995-10-17
US08/544,130 1995-10-17

Publications (2)

Publication Number Publication Date
WO1997014792A2 WO1997014792A2 (en) 1997-04-24
WO1997014792A3 true WO1997014792A3 (en) 1997-05-15

Family

ID=24170876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/013307 WO1997014792A2 (en) 1995-10-17 1996-08-19 Oligonucleotides with anti-respiratory syncytial virus activity

Country Status (2)

Country Link
AU (1) AU6848396A (en)
WO (1) WO1997014792A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US6562955B2 (en) * 2000-03-17 2003-05-13 Tosoh Corporation Oligonucleotides for detection of Vibrio parahaemolyticus and detection method for Vibrio parahaemolyticus using the same oligonucleotides
US20060089324A1 (en) * 2004-10-22 2006-04-27 Sailen Barik RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US7790878B2 (en) 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
EA012573B1 (en) * 2005-01-07 2009-10-30 Элнилэм Фармасьютикалз, Инк. Rnamodulation of rsv and therapeutic uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022553A1 (en) * 1994-02-18 1995-08-24 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022553A1 (en) * 1994-02-18 1995-08-24 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLLINS, P. & WERTZ, G.: "The envelope-associated 22k protein of human respiratory syncytial virus: nucleotide sequence of the mRNA and related polytranscript", JOURNAL OF VIROLOGY, vol. 54, April 1985 (1985-04-01), pages 65 - 71, XP002023271 *
COLLINS, P. ET AL.: "Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 83, July 1986 (1986-07-01), WASHINGTON US, pages 4594 - 4598, XP002023270 *
CRISTINA, J. ET AL.: "Analysis of genetic variability in human respiratory syncytial virus by the RNase A mismatch cleavage method: subtype divergence and heterogeneity.", VIROLOGY, (1990 JAN) 174 (1) 126-34., XP000616280 *

Also Published As

Publication number Publication date
AU6848396A (en) 1997-05-07
WO1997014792A2 (en) 1997-04-24

Similar Documents

Publication Publication Date Title
EP0745090A1 (en) Oligonucleotides with anti-respiratory syncytial virus activity
EP1035870A4 (en) Compositions and methods for treatment of hepatitis c virus-associated diseases
WO2003063771A3 (en) N4-acylcytosine nucleosides for treatment of viral iinfections
DK0662157T3 (en) Preparations and Methods for the Treatment of Hepatitis C Virus-Associated Diseases
EP1162196A4 (en) Fused-ring compounds and use thereof as drugs
NO954217L (en) Guanosine-rich antivirus oligonucleotides
CA2215190A1 (en) Aryl-ester phosphoramidate derivatives of nucleosides
CA2223776A1 (en) Method of treatment for lung diseases using antisense oligonucleotides
WO2002100415A3 (en) 4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
DZ1869A1 (en) New erythromycin derivatives, their preparation process and their use as medicaments.
WO2002032920A3 (en) Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
WO2004046159A8 (en) Antiviral nucleoside derivatives
WO2003026589A3 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
DZ1878A1 (en) New erythromycin derivatives, their preparation process and their use as drugs.
EP1669364A3 (en) Methods and compositions for treating hepatitis C virus
EP2338996A3 (en) Methods and compositions for reducing viral genome amounts in a target cell
WO1998013501A3 (en) 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
CA2107709A1 (en) Calcium Agent for Plants
MA26435A1 (en) AMIDO-SUBSTITUTED BENZYLAMINE DERIVATIVES, THEIR PRECURSOR DERIVATIVES FOR MEDICAMENTS, THEIR PREPARATION PROCESSES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND TREATMENT METHOD USING THE SAME.
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
WO1997014792A3 (en) Oligonucleotides with anti-respiratory syncytial virus activity
CA2380924A1 (en) Compositions for treating viral infections, and methods therefor
ZA991029B (en) Composition and methods for treatment of hiv infections.
EP2071030A3 (en) Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus
NO965017L (en) Oligonucleotides with anti-cytomegalovirus activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97515795

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA